J
James B. Hermiller
Researcher at St Vincent Hospital
Publications - 242
Citations - 22852
James B. Hermiller is an academic researcher from St Vincent Hospital. The author has contributed to research in topics: Stent & Percutaneous coronary intervention. The author has an hindex of 58, co-authored 230 publications receiving 20768 citations. Previous affiliations of James B. Hermiller include American College of Cardiology & University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
Gregg W. Stone,Stephen G. Ellis,David A. Cox,James B. Hermiller,Charles O'Shaughnessy,James Tift Mann,Mark Turco,Ronald P. Caputo,Patrick Bergin,Joel Greenberg,Jeffrey J. Popma,Mary E. Russell +11 more
TL;DR: As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.
Journal ArticleDOI
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis
David H. Adams,Jeffrey J. Popma,Michael J. Reardon,Steven J. Yakubov,Joseph S. Coselli,G. Michael Deeb,Thomas G. Gleason,Maurice Buchbinder,James B. Hermiller,Neal S. Kleiman,Stan Chetcuti,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,John V. Conte,Brijeshwar Maini,Mubashir Mumtaz,Sharla Chenoweth,Jae K. Oh +23 more
TL;DR: In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aorti-valve bioprosthesis was associated with a significantly higher rate of survival at 1 year than surgical aorticsvalve replacement.
Journal ArticleDOI
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Laura Mauri,Dean J. Kereiakes,Robert W. Yeh,Priscilla Driscoll-Shempp,Donald E. Cutlip,P. Gabriel Steg,P. Gabriel Steg,Sharon-Lise T. Normand,Eugene Braunwald,Stephen D. Wiviott,David J. Cohen,David R. Holmes,Mitchell W. Krucoff,James B. Hermiller,Harold L. Dauerman,Daniel I. Simon,David E. Kandzari,Kirk N. Garratt,David P. Lee,Thomas K. Pow,Peter Ver Lee,Michael J. Rinaldi,Joseph M. Massaro,Joseph M. Massaro +23 more
TL;DR: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding.
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction
Joshua M. Hare,Jay H. Traverse,Timothy D. Henry,Nabil Dib,Robert K. Strumpf,Steven P. Schulman,Gary Gerstenblith,Anthony N. DeMaria,Ali E. Denktas,Roger Gammon,James B. Hermiller,Mark A. Reisman,Gary L. Schaer,Warren Sherman +13 more
TL;DR: This trial provides pivotal safety and provisional efficacy data for an allogeneic bone marrow-derived stem cell in post-infarction patients and indicates intravenousAllogeneic hMSCs are safe in patients after acute MI.
Journal ArticleDOI
Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery.
Jeffrey J. Popma,David H. Adams,Michael J. Reardon,Steven J. Yakubov,Neal S. Kleiman,David Heimansohn,James B. Hermiller,G. Chad Hughes,J. Kevin Harrison,Joseph S. Coselli,Jose G Diez,Ali Kafi,Theodore Schreiber,Thomas G. Gleason,John V. Conte,Maurice Buchbinder,G. Michael Deeb,Blase A. Carabello,Patrick W. Serruys,Sharla Chenoweth,Jae K. Oh +20 more
TL;DR: TAVR with a self-expanding bioprosthesis was safe and effective in patients with symptomatic severe aortic stenosis at prohibitive risk for surgical valve replacement.